3P Biopharmaceuticals lands in the United States.

The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.

3P Biopharmaceuticals advances its international expansion with the opening of its first commercial office in the United States located in Boston, Massachusetts.

A company based in Navarre, Spain, with a 16-year history as an international CDMO, has taken a major step forward to expand its presence within the US market. This marks 3P’s first venture outside of Spain, strategically placing the company at the center of the world´s largest biopharma hub. According to Dámaso Molero, CEO of the company, “The United States is considered one of the largest and most dynamic markets for biopharma worldwide. Establishing ourselves in Boston will allow 3P to access a broad and fast-growing market, enabling us to further drive our growth.

In terms of global positioning, this endeavor will provide the Navarre-based CDMO with greater visibility and international recognition. This initial step into the American market will further enable the company to meet with new and existing clients and foster long-term partnerships with US-based companies. Elena Erroba, Chief Commercial Officer at 3P, highlights, “3P has always seen the undeniable business opportunity in the United States. This new commercial office will assist us in meeting the growing demands of our customers and consolidating our CDMO offering in North America.

This strategic expansion is supported by Keensight Capital’s Boston office. This physical presence in Boston helps Keensight reinforce the firm’s commitment to supporting the growth of its portfolio companies in North America.

This major development holds significant importance, given the city’s long-standing history in the field of biopharma. Many leading global biopharma companies have their headquarters there, making it a highly attractive and dynamic city. Furthermore, the city’s concentration of renowned academic and research institutions, coupled with the collaborative efforts between academia and industry, create an unparalleled entrepreneurial ecosystem.

3P is firmly committed to expanding its global presence in the biologics manufacturing sector as it embarks on this effort to broaden its global footprint. With its unwavering commitment to providing exceptional biologics manufacturing services, 3P aims to make a lasting mark on the world stage, setting new benchmarks of excellence in the industry.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

The Regional Minister for Economic and Business Development Mikel Irujo meets with the management of 3P Biopharmaceuticals and its majority shareholder Keensight Capital.

Published: 23rd March 2023
During the meeting, attendees evaluated 3P's trajectory and its investment plan for the next five years.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.